While studies have failed to support any prognostic value for overexpression of HER2 in CRC, it is present in up 14–81% of CRC cases and HER2 overexpression has also been demonstrated to be predictive of resistance to anti-EGFR treatment [93,94]. This evidence concerns the gene ERBB2 and colorectal carcinoma.